Resmed Inc
RMD- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000943819
In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 891 institutions reported holding it in 13F filings for Q2 2026, worth $19.4B in total; Giverny Capital is the only superinvestor holding it.
Other share classesRSMDF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $5.26M in total
- 5
- 13F holdersQ2 2026, −44 vs. previous quarter
- 891
- 13F valueReported value at the end of Q2 2026
- $19.4B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding RMD, Q2 2026
1 superinvestor reports holding Resmed Inc on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Resmed Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)6:40 AM ET | Sep 8 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $222.44 | −$1.11M | −1.1%466.3K after | 10b5-1 |
| Sep 4, 2026 (view filing)6:30 AM ET | Sep 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −970 | $234.73 | −$227.7K | −1.8%51.8K after | 10b5-1 |
| Aug 11, 2026 (view filing)6:30 AM ET | Aug 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $205.69 | −$1.03M | −1.1%466.3K after | 10b5-1 |
| Aug 6, 2026 (view filing)2:29 PM ET | Aug 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −8.00K | $225.00 | −$1.80M | −13.2%52.8K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:40 AM ET | Jul 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $218.55 | −$1.09M | −1.1%466.2K after | 10b5-1 |
| Jun 9, 2026 (view filing) | Jun 8 | 1 day | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $193.96 | −$968.1K | −1.1%466.3K after | 10b5-1 |
| May 11, 2026 (view filing) | May 7 | 4 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $207.82 | −$1.04M | −1.1%466.2K after | 10b5-1 |
| Apr 9, 2026 (view filing) | Apr 7 | 2 days | Farrell Michael J.Chairman and CEO | SSaleResMed Common Stock | −4.99K | $225.50 | −$1.13M | −1.1%466.2K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −1.00K | $224.31 | −$224.3K | −1.2%83.5K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $225.00 | −$450.0K | −3.2%60.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Resmed Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,317,194 | $2.40B | 0.04% | +223,171+1.8% | Added |
| Vanguard Capital Management LLC | 9,474,129 | $1.85B | 0.04% | +7,713+0.1% | Added |
| Vanguard Portfolio Management LLC | 7,913,661 | $1.54B | 0.07% | +49,739+0.6% | Added |
| State Street Corp | 6,680,735 | $1.30B | 0.04% | +37,567+0.6% | Added |
| Geode Capital Management, LLC | 4,352,320 | $845.2M | 0.05% | −5530.0% | Reduced |
| Bank of New York Mellon Corp | 4,197,610 | $818.0M | 0.13% | −727,776−14.8% | Reduced |
| First Trust Advisors LP | 2,278,696 | $444.1M | 0.26% | +740,871+48.2% | Added |
| Invesco Ltd. | 2,063,578 | $402.1M | 0.03% | +106,964+5.5% | Added |
| Morgan Stanley | 1,928,931 | $375.9M | 0.02% | −757,890−28.2% | Reduced |
| Northern Trust Corp | 1,696,674 | $330.6M | 0.04% | −29,019−1.7% | Reduced |